TY - JOUR
T1 - The role of glycogen synthase kinase 3β in insulin-stimulated glucose metabolism
AU - Summers, Scott A.
AU - Kao, Aimee W.
AU - Kohn, Aimee D.
AU - Backus, Gillian S.
AU - Roth, Richard A.
AU - Pessin, Jeffrey E.
AU - Birnbaum, Morris J.
PY - 1999/6/18
Y1 - 1999/6/18
N2 - To characterize the contribution of glycogen synthase kinase 3β (GSK3β) inactivation to insulin-stimulated glucose metabolism, wild-type (WT-GSK), catalytically inactive (KM-GSK), and uninhibitable (S9A-GSK) forms of GSK3β were expressed in insulin-responsive 3T3-L1 adipocytes using adenovirus technology. WT-GSK, but not KM-GSK, reduced basal and insulin- stimulated glycogen synthase activity without affecting the -fold stimulation of the enzyme by insulin. S9A-GSK similarly decreased cellular glycogen synthase activity, but also partially blocked insulin stimulation of the enzyme. S9A-GSK expression also markedly inhibited insulin stimulation of IRS-1-associated phosphatidylinositol 3-kinase activity, but only weakly inhibited insulin-stimulated Akt/PKB phosphorylation and glucose uptake, with no effect on GLUT4 translocation. To further evaluate the role of GSK3β in insulin signaling, the GSK3β inhibitor lithium was used to mimic the consequences of insulin-stimulated GSK3β inactivation. Although lithium stimulated the incorporation of glucose into glycogen and glycogen synthase enzyme activity, the inhibitor was without effect on GLUT4 translocation and pp70 S6 kinase. Lithium stimulation of glycogen synthesis was insensitive to wortmannin, which is consistent with its acting directly on GSK3β downstream of phosphatidylinositol 3-kinase. These data support the hypothesis that GSK3β contributes to insulin regulation of glycogen synthesis, but is not responsible for the increase in glucose transport.
AB - To characterize the contribution of glycogen synthase kinase 3β (GSK3β) inactivation to insulin-stimulated glucose metabolism, wild-type (WT-GSK), catalytically inactive (KM-GSK), and uninhibitable (S9A-GSK) forms of GSK3β were expressed in insulin-responsive 3T3-L1 adipocytes using adenovirus technology. WT-GSK, but not KM-GSK, reduced basal and insulin- stimulated glycogen synthase activity without affecting the -fold stimulation of the enzyme by insulin. S9A-GSK similarly decreased cellular glycogen synthase activity, but also partially blocked insulin stimulation of the enzyme. S9A-GSK expression also markedly inhibited insulin stimulation of IRS-1-associated phosphatidylinositol 3-kinase activity, but only weakly inhibited insulin-stimulated Akt/PKB phosphorylation and glucose uptake, with no effect on GLUT4 translocation. To further evaluate the role of GSK3β in insulin signaling, the GSK3β inhibitor lithium was used to mimic the consequences of insulin-stimulated GSK3β inactivation. Although lithium stimulated the incorporation of glucose into glycogen and glycogen synthase enzyme activity, the inhibitor was without effect on GLUT4 translocation and pp70 S6 kinase. Lithium stimulation of glycogen synthesis was insensitive to wortmannin, which is consistent with its acting directly on GSK3β downstream of phosphatidylinositol 3-kinase. These data support the hypothesis that GSK3β contributes to insulin regulation of glycogen synthesis, but is not responsible for the increase in glucose transport.
UR - http://www.scopus.com/inward/record.url?scp=0033580912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033580912&partnerID=8YFLogxK
U2 - 10.1074/jbc.274.25.17934
DO - 10.1074/jbc.274.25.17934
M3 - Article
C2 - 10364240
AN - SCOPUS:0033580912
SN - 0021-9258
VL - 274
SP - 17934
EP - 17940
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 25
ER -